Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021;41(5):863–77.

Article  PubMed  Google Scholar 

Canada, AAo. The impact of arthritis in Canada: today and over the next 30 years. 2011. http://www.ergoresearchcom/wp-content/uploads/2012/04/Impact%2520on%2520arthrisis%2520in%2520Canada_Today%2520and%2520over%2520the%2520next%252030%2520yearspdf.

Smolen JS. Treat to target in Rheumatology: a historical account on occasion of the 10th anniversary. Rheum Dis Clin North Am. 2019;45(4):477–85.

Article  PubMed  Google Scholar 

de Hair MJH, Jacobs JWG, Schoneveld JLM, van Laar JM. Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford). 2018;57(7):1135–44.

PubMed  Google Scholar 

Takanashi S, Kaneko Y, Takeuchi T. Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice. Rheumatology (Oxford). 2021;60(11):5247–56.

Article  CAS  PubMed  Google Scholar 

Roodenrijs NMT, van der Goes MC, Welsing PMJ, Tekstra J, Lafeber F, Jacobs JWG, et al. Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease. Rheumatology (Oxford). 2021;60(8):3778–88.

Article  PubMed  Google Scholar 

Roodenrijs NMT, Welsing PMJ, van der Goes MC, Tekstra J, Lafeber F, Jacobs JWG, et al. Health care utilisation and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study. Rheumatology (Oxford). 2021;60(10):4681–4690. https://doi.org/10.1093/rheumatology/keab078

Kearsley-Fleet L, Davies R, De Cock D, Watson KD, Lunt M, Buch MH, et al. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018;77(10):1405–12.

Article  PubMed  Google Scholar 

Novella-Navarro M, Plasencia C, Tornero C, Navarro-Compan V, Cabrera-Alarcon JL, Peiteado-Lopez D, et al. Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):284.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ochi S, Mizoguchi F, Nakano K, Tanaka Y. Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry. Clin Exp Rheumatol. 2022;40(1):86–96.

Article  PubMed  Google Scholar 

Roodenrijs NMT, Hamar A, Kedves M, Nagy G, van Laar JM, van der Heijde D, et al. Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD open. 2021;7(1):e001512.

Roodenrijs NMT, Kedves M, Hamar A, Nagy G, van Laar JM, van der Heijde D, et al. Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD open. 2021;7(1):e001511.

Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, et al. Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis. 2018;77(12):1705–9.

Article  CAS  PubMed  Google Scholar 

Nagy G, Roodenrijs NMT, Welsing PM, Kedves M, Hamar A, van der Goes MC, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(1):31–5.

Article  PubMed  Google Scholar 

Nagy G, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, van der Goes MC, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022;81(1):20–33.

Article  CAS  PubMed  Google Scholar 

Leon L, Madrid-Garcia A, Lopez-Viejo P, Gonzalez-Alvaro I, Novella-Navarro M, Freites Nunez D, et al. Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease. RMD open. 2023;9(1):e002842.

Tan Y, Buch MH. ‘Difficult to treat’ rheumatoid arthritis: current position and considerations for next steps. RMD open. 2022;8(2):e002387.

Watanabe R, Hashimoto M, Murata K, Murakami K, Tanaka M, Ohmura K, et al. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort. Immunological Med. 2021:1–10.

Dey M, Nagy G, Nikiphorou E. Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin? Rheumatology (Oxford). 2023;62(5):1773–9.

Article  CAS  PubMed  Google Scholar 

Conran C, Kolfenbach J, Kuhn K, Striebich C, Moreland L. A review of difficult-to-treat rheumatoid arthritis: definition, clinical presentation, and management. Curr Rheumatol Rep. 2023;25(12):285–94.

Article  PubMed  Google Scholar 

Roodenrijs NMT, van der Goes MC, Welsing PMJ, van Oorschot EPC, Nikiphorou E, Nijhof NC, et al. Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study. Rheumatology (Oxford). 2021;60(11):5105–16.

Article  PubMed  Google Scholar 

Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–39.

Article  Google Scholar 

Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99.

Article  CAS  PubMed  Google Scholar 

Haraoui B, Jovaisas A, Bensen WG, Faraawi R, Kelsall J, Dixit S, et al. Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population. RMD open. 2015;1(1):e000078.

Article  PubMed  PubMed Central  Google Scholar 

Andersen KM, Schieir O, Valois MF, Bartlett SJ, Bessette L, Boire G, et al. A bridge too far? Real-world practice patterns of early glucocorticoid use in the Canadian early arthritis cohort. ACR Open Rheumatol. 2022;4(1):57–64.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.

Michitsuji T, Fukui S, Morimoto S, Endo Y, Nishino A, Nishihata S, et al. Clinical and ultrasound features of difficult-to-treat rheumatoid arthritis: a multicenter RA ultrasound cohort study. Scand J Rheumatol. 2024;53(2):123–9.

Article  CAS  PubMed  Google Scholar 

Garcia-Salinas R, Sanchez-Prado E, Mareco J, Ronald P, Ruta S, Gomez R, et al. Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations. Rheumatol Int. 2023;43(10):1821–8.

Article  CAS  PubMed  Google Scholar 

Zangi HA, Ndosi M, Adams J, Andersen L, Bode C, Bostrom C, et al. EULAR recommendations for patient education for people with inflammatory arthritis. Ann Rheum Dis. 2015;74(6):954–62.

Article  CAS  PubMed  Google Scholar 

Novella-Navarro M, Ruiz-Esquide V, Torres-Ortiz G, Chacur CA, Tornero C, Fernandez-Fernandez E, et al. A paradigm of difficult-to-treat rheumatoid arthritis: subtypes and early identification. Clin Exp Rheumatol. 2023;41(5):1114–9.

PubMed  Google Scholar 

Takanashi S, Kaneko Y, Takeuchi T. Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(11):1491–3.

Article  PubMed  Google Scholar 

Ochi S, Sonomoto K, Nakayamada S, Tanaka Y. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Res Ther. 2022;24(1):61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Watanabe R, Okano T, Gon T, Yoshida N, Fukumoto K, Yamada S, et al. Difficult-to-treat rheumatoid arthritis: current concept and unsolved problems. Front Med (Lausanne). 2022;9:1049875.

Article  PubMed  Google Scholar 

Hecquet S, Combier A, Steelandt A, Pons M, Wendling D, Molto A, et al. Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital. Rheumatology (Oxford). 2023;62(12):3866–74.

Article  PubMed  Google Scholar 

Simon LS, Taylor PC, Choy EH, Sebba A, Quebe A, Knopp KL, et al. The Jak/STAT pathway: a focus on pain in rheumatoid arthritis. Semin Arthritis Rheum. 2021;51(1):278–84.

Article  CAS  PubMed  Google Scholar 

Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging Clinical Data. J Inflamm Res. 2020;13:519–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316–26.

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2022. https://www.fdagov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed 31 Jan 2022.

European Medicines Agency, Xeljanz. 2022. https://www.emaeuropaeu/en/medicines/human/referrals/xeljanz#:~:text=On%2014%20November%20EMA%20concluded,high%20risk%20of%20blood%20clots. Accessed 31 Jan 2022.

Giollo A, Zen M, Larosa M, Astorri D, Salvato M, Calligaro A, et al. Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: a multicentre cohort study. Rheumatology (Oxford). 2023;62(6):2083